| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
The primary biological targets of Tigloylgomisin P are not definitively established. It is known to have anti-HIV activity and potential anticancer effects. The compound exhibits cytotoxicity against A549 lung cancer cells and nasopharyngeal epidermoid carcinoma (KB) cells. Its mechanism of action may involve interaction with viral or cellular targets, but the specific molecular targets remain to be fully elucidated.
|
|---|---|
| ln Vitro |
Tigloylgomisin P exhibits a low level of cytotoxicity against A549 cells (GI50=18.77 μM) and nasopharyngeal epidermoid carcinoma (KB; GI50=13.91 μM)[1].
In vitro, Tigloylgomisin P exhibits a low level of cytotoxicity against A549 cells (GI50 = 18.77 μM) and nasopharyngeal epidermoid carcinoma (KB; GI50 = 13.91 μM). These data indicate that the compound has moderate cytotoxic activity against these cancer cell lines. The anti-HIV activity is characterized by an EC50 of 37 μM, suggesting that higher concentrations are required for antiviral effects compared to its cytotoxic activity. |
| ln Vivo |
In vivo data for Tigloylgomisin P are not available in the literature. As a natural product with anti-HIV and anticancer potential, further studies would be needed to evaluate its efficacy and safety in animal models. The compound's pharmacokinetic properties and in vivo activity remain to be characterized, and it is currently in the early stages of research.
|
| Enzyme Assay |
Specific in vitro enzyme/receptor binding assay protocols for Tigloylgomisin P have not been reported. As a natural product with anti-HIV activity, its mechanism of action may involve inhibition of viral enzymes or interference with viral entry or replication. Standard antiviral assays, such as those measuring inhibition of HIV replication in infected cells, are typically used to assess its activity. Further biochemical studies are needed to identify its direct molecular targets.
|
| Cell Assay |
Cellular assays for Tigloylgomisin P are performed using cancer cell lines such as A549 (lung cancer) and KB (nasopharyngeal epidermoid carcinoma) cells. Cells are treated with various concentrations of the compound, and cell viability is assessed to determine GI50 values. Anti-HIV activity is evaluated using HIV-infected cell cultures, where the compound's ability to inhibit viral replication is measured. Standard cytotoxicity assays are also conducted to assess its safety profile.
|
| Animal Protocol |
In vivo animal protocols for Tigloylgomisin P are not available in the literature. As a natural product with potential therapeutic applications, it would typically be evaluated in mouse models of HIV infection or cancer. However, such studies have not been reported for this compound. Currently, Tigloylgomisin P remains at the in vitro research stage, and further studies are needed to explore its in vivo efficacy.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties of Tigloylgomisin P have not been characterized. As a natural lignan, its absorption, distribution, metabolism, and excretion (ADME) profile would need to be investigated to assess its drug-like properties. The compound is typically stored as a powder at -20°C and may be soluble in DMSO. Its solubility in aqueous media is limited, with a calculated value of 4.8E-3 g/L at 25°C.
|
| Toxicity/Toxicokinetics |
Toxicity data for Tigloylgomisin P are limited. It exhibits low-level cytotoxicity against A549 and KB cell lines, with GI50 values of 18.77 μM and 13.91 μM, respectively. These data suggest moderate cytotoxic potential. Comprehensive toxicological studies, including in vivo safety assessments, have not been conducted. The compound is intended for research use only and is not approved for human therapeutic use.
|
| References | |
| Additional Infomation |
Schisandrin P has been reported to be present in Schisandra chinensis, Schisandra chinensis, and other organisms with relevant data.
See also: Schisandra chinensis fruit (partial). Tigloylgomisin P is also known as crotonylgomisin P and is a natural lignin with anti-HIV and potential anticancer activities. It is isolated from Schisandra species and is a member of the dibenzocyclooctadiene lignan family. The compound is not currently in clinical trials and has not been approved for therapeutic use. Further research is needed to elucidate its mechanism of action and therapeutic potential. |
| Molecular Formula |
C28H34O9
|
|---|---|
| Molecular Weight |
514.56
|
| Exact Mass |
514.22
|
| CAS # |
69176-51-8
|
| PubChem CID |
5318785
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.61
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
37
|
| Complexity |
833
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
C/C=C(\C)/C(=O)O[C@@H]1C2=CC(=C(C(=C2C3=C(C4=C(C=C3C[C@@H]([C@@]1(C)O)C)OCO4)OC)OC)OC)OC
|
| InChi Key |
BKGUPIVDQHHVMV-TWJXSMCESA-N
|
| InChi Code |
InChI=1S/C28H34O9/c1-9-14(2)27(29)37-26-17-12-18(31-5)22(32-6)25(34-8)21(17)20-16(10-15(3)28(26,4)30)11-19-23(24(20)33-7)36-13-35-19/h9,11-12,15,26,30H,10,13H2,1-8H3/b14-9+/t15-,26+,28+/m0/s1
|
| Chemical Name |
[(8R,9R,10S)-9-hydroxy-3,4,5,19-tetramethoxy-9,10-dimethyl-15,17-dioxatetracyclo[10.7.0.02,7.014,18]nonadeca-1(19),2,4,6,12,14(18)-hexaen-8-yl] (E)-2-methylbut-2-enoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9434 mL | 9.7170 mL | 19.4341 mL | |
| 5 mM | 0.3887 mL | 1.9434 mL | 3.8868 mL | |
| 10 mM | 0.1943 mL | 0.9717 mL | 1.9434 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
